Two perspectives on venous thromboembolism in oncology
Authors:
Patrik Palacka 1; Jana Hirmerová 2,3
Authors‘ workplace:
II. onkologická klinika LF UK a Národného onkologického ústavu Bratislava, Slovenská republika
1; II. interní klinika LF UK a FN Plzeň
2; Biomedicínské centrum LF UK, Plzeň
3
Published in:
Vnitř Lék 2017; 63(6): 431-440
Category:
Reviews
Tento přehledný referát slovenského onkologa a české angioložky byl redakci poskytnut v mateřském jazyce obou autorů a redakce se rozhodla jej ponechat v jazykovém znění rukopisu.
Overview
An increased risk of venous thromboembolism (VTE) in patients with malignancy compared with the current population is determined by risk factors including the use of anticancer treatments, in particular some hormonal drugs, cytostatics, vascular endothelial growth factor (VEGF) inhibitors and epidermal receptor growth factor (EGFR) inhibitors, immunomodulators, and erythropoietins. The population of cancer patients is divided into a group of individuals with a history of malignant disease in complete remission and patients with active (locally advanced or metastatic) malignant disease in terms of approach to VTE.
Venous thromboembolism negatively influences the prognosis of a patient with malignancy. Cancer associated VTE is associated with higher risk of recurrence as well as higher risk of bleeding during anticoagulation. For initial and long-term treatment, low molecular weight heparin should be preferred, for a minimum of 3–6 months. Some subgroups deserve a special approach – patients with thrombocytopenia, renal insufficiency, and patients with recurrent VTE despite anticoagulation. The treatment of an incidental pulmonary embolism is another controversial issue. The approach to a patient with cancer associated VTE should be individualized and should take into account patient´s overall prognosis and risk/benefit ratio of treatment.
Key words:
anticoagulation treatment – cancer – risk factors – venous thromboembolism
Sources
1. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med 2012; 9(7): e1001275. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pmed.1001275>.
2. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27(29): 4834–4838. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2009.22.6324>.
3. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6(2): 127–137.
4. Zwicker JI, Liebman HA, Neuberg D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15(22): 6830–6840. Dostupné z DOI: <http://dx.doi.org/10.1158/1078–0432.CCR-09–0371>.
5. Hedderich, GS, O‘Connor RJ, Reid EC et al. Caval tumor thrombus complicating renal cell carcinoma: a surgical challenge. Surgery 1987; 102(4): 614–621.
6. Amir E, Seruga B, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103(17): 1299–1309. Dostupné z DOI: <http://dx.doi.org/10.1093/jnci/djr242>.
7. Thürlimann B, Castiglione M, Hsu-Schmitz SF et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997; 33(7): 1017–1024.
8. Seng S, Liu Z, Chiu SK et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012; 30(35): 4416–4426. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2012.42.4358>.
9. Grace RF, Dahlberg SE, Neuberg D et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011; 152(4): 452–459. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2010.08524.x>.
10. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300(19): 2277–2285. Dostupné z DOI: <http://dx.doi.org10.1001/jama.2008.656>.
11. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99(16): 1232–1239. Erratum in J Natl Cancer Inst 2008; 100(2): 156. J Natl Cancer Inst 2008; 100(9): 685.
12. Hurwitz HI, Saltz LB, Van Cutsem E et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011; 29(13): 1757–1764. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.32.3220>.
13. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30(28): 3499–3506.
14. Petrelli F, Cabiddu M, Borgonovo K et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012; 23(7): 1672–1679. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdr592>
15. Miroddi M, Sterrantino C, Simmonds M et al. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). Int J Cancer 2016; 139(10): 2370–2380. Dostupné z DOI: <http://dx.doi.org/10.1002/ijc.30280>.
16. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414–423.
17. Tonia T, Mettler A, Robert N et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD003407.pub5>.
18. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146–153
19. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23(10): 2123–2129.
20. Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119(12): 1062–1072.
21. Lee AY, Kamphuisen PW, Meyer G et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA 2015; 314(7): 677–686. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.9243>.
22. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162(15): 1729–1735.
23. Deitcher SR, Kessler CM, Merli G et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12(4): 389–396.
24. Akl EA, Kahale L, Barba M et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; (7): CD006650. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD006650.pub4>.
25. Pollack jr. CV, Reilly PA, Eikelboom J et al. Idarucizubam fo dabigatran reversal. N Engl J Med 2015; 373(6): 511–520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1502000>.
26. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13(12): 2187–2191. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.13153>.
27. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114(1): 150–157. Dostupné z DOI: <http://dx.doi.org/10.1160/TH14–11–0977>.
28. Prins MH, Lensing AW, Bauersachs R et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11(1): 21. Dostupné z DOI: <http://dx.doi.org/10.1186/1477–9560–11–21>.
29. Vedovati MC, Germini F, Agnelli G et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147(2): 475–483. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14–0402>.
30. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293(6): 715–722.
31. Timp JF, Braekkan SK, Versteeg HH et al. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122(10): 1712–1723. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013–04–460121>.
32. Gussoni G, Frasson S, La Regina M et al. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131(1): 24–30. Dostupné z DOI: <http://dx.doi.org/10.1016/j.thromres.2012.10.007>.
33. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100(10): 3484–3488.
34. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017; 117(2): 219–230. Dostupné z DOI: <http://dx.doi.orG/10.1160/TH16–08–0615>.
35. Righini M, Le Gal G, De Lucia S et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost 2006; 95(4): 715–719.
36. Carrier M, Lee AY, Bates SM et al. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res 2008; 123(1): 177–183. Dostupné z DOI: <http://dx.doi.org/10.1016/j.thromres.2008.05.002>.
37. Cosmi B, Filippini M, Tonti D et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 2012; 10(6): 1026–1035. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1538–7836.2012.04727.x>.
38. Mouton WG, Kienle Y, Muggli B et al. Tumors associated with superficial thrombophlebitis. Vasa 2009; 38(2): 167–170. Dostupné z DOI: <http://dx.doi.org/10.1024/0301–1526.38.2.167>.
39. Ageno W, Grimwood R, Limbiati S et al. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica 2005; 90(2): 220–224.
40. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013; 122(14): 2310–2317. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013–04–460162>.
41. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.
42. Kessler P. Prophylaxis and treatment of thromboembolism in oncology. Vnitř Lék 2009; 55(3): 219–222.
43. Short NJ, Connors JM. New Oral Anticoagulants and the Cancer Patient. Oncologist 2014; 19(1): 82–93. Dostupné z DOI: <http://dx.doi.org/10.1634/theoncologist.2013–0239>.
44. Sardar P, Chatterjee S, Herzog E et al. New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther 2015; 22(6): 460–468. Dostupné z DOI: <http://dx.doi.org/10.1097/MJT.0000000000000055>.
45. Louzada ML, Carrier M, Lazo-Langner A et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126(4): 448–454. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.111.051920>.
46. van der Wall SJ, Klok FA, den Exter PL et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost 2017; 15(1): 74–79. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.13563>.
47. Schulman S, Zondag M, Linkins L et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost 2015; 13(6): 1010–1018. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.12955>.
48. Brunson A, Ho G, White R et al. Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study. Thromb Res 2017; 153: 57–64. Dostupné z DOI: <http://dx.doi.org/10.1016/j.thromres.2017.03.012>.
49. den Exter PL, Hooijer J, Dekkers OM et al. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29(17): 2405–2409. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.34.0984>.
50. van der Hulle T, den Exter PL, Planquette B et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 2016; 14(1): 105–113. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.13172>.
51. O‘Connell C. How I treat incidental pulmonary embolism. Blood 2015; 125(12): 1877–1882. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2014–08–551879>.
52. Palareti G How I treat isolated distal deep vein thrombosis (IDDVT). Blood 2014; 123(12): 1802–1809. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013–10–512616>.
53. Carrier M, Lazo-Langner A, Shivakumar S et al. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol 2015; 22(1): 49–59. Dostupné z DOI: <http://dx.doi.org/10.3747/co.22.2392>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 6
Most read in this issue
- Primary testicular lymphoma
- “Snags” connected with establishing the vitamin D
- Insulin pump in type 2 diabetes: B-cell focused treatment
- Two perspectives on venous thromboembolism in oncology